Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGSWW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GeneDx Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GeneDx Holdings's regulatory disclosures and financial reporting.
Amendment No. 9 to the Schedule 13D for GeneDx Holdings Corp. updates ownership and voting information for a group led by Eli Casdin and Keith Meister. The filing shows that Eli Casdin beneficially owns 3,599,671 shares (12.4%) and Keith A. Meister beneficially owns 3,630,826 shares (12.5%) of the Class A common stock, based on 28,726,248 shares outstanding as of July 24, 2025.
The filing attributes 3,007,164 shares (10.5%) to Casdin Partners Master Fund, L.P. and 3,058,629 shares (10.6%) to investment funds advised by Corvex Management LP. Certain reported holdings include shares issuable upon exercise of warrants and vested options (including 204,141 private placement warrants exercisable at $379.50 per share). The funds for the purchases listed were from the working capital of Casdin Partners Master Fund, L.P. Transactions in the past 60 days are reported in Exhibit B. The Amendment supplements earlier Schedule 13D filings and includes a joint filing agreement and transaction schedule as exhibits.